There is concern about the potential exploitation of children who are enrolled into clinical trials in developing and transition countries. Previous studies of globalization have only examined pediatric drug trials, and only 1 study has provided patient-level data by country.
For .2 decades, progressive changes in US and, recently, European legislation have created a transatlantic framework of complementary incentives and obligations that are intended to increase the development and availability of ageappropriate medicines for pediatric use. [1] [2] [3] [4] [5] [6] Consequently, the numbers of pediatric clinical trials are increasing. However, a relatively limited pediatric population is available for enrollment, and the target population may be dispersed geographically. These factors, along with the trends in increasing globalization of clinical research, cause concern about the potential for exploitation in developing and transition countries of the already vulnerable pediatric population. 7, 8 In 2010, we published an analysis of pediatric drug studies received and assessed by the US Food and Drug Administration (FDA) between February 2002 and March 2007 in response to written requests issued by the FDA under the Best Pharmaceuticals for Children Act of 2002 (BPCA; the "pediatric exclusivity" provision). This is referred to hereafter as the 2002-2007 cohort. 9 This was the first published analysis of pediatric clinical trials that provided data on patient enrollment by country. Although most of the studies included $1 US center and most of the patients were enrolled in the United States, 38% of the studies included centers in developing or transition countries, and 23% of the patients were enrolled from developing or transition countries. We wished to explore any change in the pattern of study location and patient enrollment for pediatric drug trials, particularly after the entry into force of the European pediatric medicines legislation in January 2007, which introduced a framework that requires earlier development of pediatric clinical trials and supports European pediatric clinical trial networks. 5 , 6 The European legislation may result in increased patient enrollment from the European Union (EU) because, increasingly, sponsors establish global pediatric clinical development programs and subsequently submit the results to both the US and the EU regulatory authorities. We also wished to analyze the locations and patient enrollment for pediatric vaccine trials because we have not done this before.
METHODS

Selection of Studies
We identified all new drugs and biologicals license applications that were approved between September 28, 2007 and December 21, 2010 and submitted to the FDA under either BPCA or the Pediatric Research Equity Act (PREA) of 2003. Within each application, we identified all completed studies that enrolled subjects aged #18 years.
Data Collection
For each application submitted to the FDA, individual completed studies that recruited pediatric subjects were identified by the sponsor-allocated trial number. The following data were extracted from each final study report: study location(s), number of trial centers that enrolled pediatric subjects per location, number of pediatric subjects enrolled per location, age range recruited, classification ofproduct (drug,biological, or vaccine), therapeutic indication, study design and duration, study sponsor, and legal basis for submission. Regional categories and the economic status of the participating countries were defined according to the United Nations classification. 10 
Analysis
To avoid double counting, long-term extensions or substudies of previously counted studies were omitted from the analysis, as were all studies that had been submitted previously to the FDA. The baseline characteristics were summarized by using descriptive statistical analysis. We also present the characteristics of the locations and patient enrollment of the pediatric trials in the 2002-2007 and 2007-2010 cohorts  as numbers with percentages. To test  whether certain proportions were significantly different between the 2 cohorts, we used a 2-tailed, unpooled Z test. We considered a P value of ,.01 to be statistically significant. We used Stata 9 statistical software (State Corp, College Station, TX) for all analyses.
RESULTS
Overview
Overall 139 applications relating to 113 medicinal products (92 drugs, 12 vaccines, and 9 other biological products) met the selection criteria. Nonvaccine biological products are referred to as biologicals. Vaccines are described separately. Twenty-nine applications contained no new pediatric studies. 
Sponsors
There were 60 different sponsors; 65% were in the pharmaceutical industry top 50 11 and 52% were US-owned. Thirty sponsors conducted trials with centers in $1 developing country. Of these sponsors, 73% (22/30) were among the top 50 pharmaceutical companies. Three pharmaceutical companies, GlaxoSmithKline, Merck, and Novartis, conducted 50% (48/96) of the studies involving developing countries; over one-third (38%, 18/48) of these were vaccine studies.
Formulations
Half of the applications (70/139) were for oral formulations (tablets, capsules, granules, sprinkles, suspensions, or solutions), 28% (39/139) were for topical formulations (administered through skin, lungs, nasal mucosa, or conjunctivae), and the remaining 22% (30/139) were for systemic formulations (injections or infusions).
Age Groups
Adolescents, children, and infants were well represented, but few studies (3.5% [15/ 
Therapeutic Indications and Therapeutic Area Studied
The studies covered a wide range of indications (n = 60) and therapeutic areas (n = 14). The 3 most commonly studied therapeutic areas overall were infectious diseases, pulmonary/allergy, and psychiatry, together representing 64% of all studies (Fig 1) . Vaccine trials accounted for 72% of all enrolled patients. The most frequently studied indications in terms of study number and patient enrollment are listed in Supplemental Tables 7 through 9 .
Study Location
Tables 2 through 4 present the top 10 countries involved in the trials, ranked by trial participation and by patient numbers. Table 5 presents data from the earlier cohort of drug studies for comparison. Supplemental Tables 10  through 12 present the participation of all countries by study involvement and patient enrollment. Regional participation is presented in Fig 2. Drugs, biologicals, and vaccines are shown separately. Overall, the United States participated in more trials and enrolled more patients than any other country, and North America participated in more trials than any other region. Just over half (51%) of all studies were conducted in the United States alone. In contrast, just under half of all studies included $1 non-US country, and 23% of all studies were conducted entirely outside the United States. The level of involvement of non-US countries increased with increasing trial size, from 36% of trials enrolling ,100 patients, to 55% of trials in those enrolling $100 patients and 61% of trials in those enrolling .500 patients.
The countries of the EU and European Economic Area (EEA) and Latin America were well represented. The participation of other individual countries and geographical regions varied according to whether the trials involved drugs and biologicals or vaccines.
Role of Developing and Transition Countries and Developing Regions
At a country level, over one-fifth of all trials (23% [96/424]) enrolled patients from $1 developing or transition country. Altogether, 41 developing or transition countries contributed to $1 pediatric trial. Of the developing or transition countries, Brazil was involved in the most trials, participating in 7% (31/424) of all trials, and Mexico enrolled the most patients, enrolling 7% (14 344/ 203 515) of all patients. Most of the patients enrolled in Mexico (97%) participated in vaccine trials. Developing countries were relatively more involved in vaccine trials than trials on drugs and biologicals. They supplied 15% (296/ 1954) of the centers and enrolled 52% (76 772/147 692) of the patients in the vaccine trials and supplied 12% (1027/ 8539) of the centers and enrolled 11% (6065/55 819) of the patients in the trials on drugs and biologicals. Of the developing regions, Latin America was the most involved in pediatric vaccine trials, participating in as many studies as all of the other developing regions together and enrolling 7 times more patients.
Most of the trials (77% [84/96]) involving developing countries also had centers (and protocol approval) in developed countries. Only 10% (8/78) of vaccine trials representing 6% of patients, and The most common therapeutic areas studied in the drugs and biologicals trials that included developing countries were pulmonary (asthma) (23%), neurology (migraine, bladder instability, and seizures) (22%), and infectious diseases (fungal and viral diseases) (21%). The least studied therapeutic areas in trials involving developing countries were rheumatology, oncology, and anesthesia.
For a few therapeutic indications, a relatively high percentage of patients were enrolled from developing countries, for example, juvenile idiopathic arthritis (JIA) (26%), bipolar disorder/schizophrenia (29%), and hypertension (34%). However, for the last 2 indications, patients were recruited from 12 and 13 different developing countries, respectively, so patient enrollment in any particular developing country was low (the mean number of patients recruited per developing country was 37 for bipolar disorder/schizophrenia and 44 for hypertension, respectively). A study in JIA recruited 94 patients from Latin America. The same study recruited 27 patients from the United States and 69 patients from Europe. 
Comparison of Drug
FIGURE 2
Regional participation in studies and patient enrollment for drugs, biologicals, and vaccines. Russia for study involvement and by EU countries, Russia, and Australia for patient enrollment. patient enrollment from developing countries. The shift reflects increased patient recruitment in the United States and decreased recruitment in Latin America, the lead developing region involved in pediatric trials. The decrease in Latin American participation may be due partly to the small number of antibiotic trials in the current sample. In the earlier cohort, the region was principally involved in large trials on antibiotics. There was no significant change in EU participation in clinical trials with respect to study involvement, although there was a statistically significant, albeit small, increase in patient enrollment. This is not surprising, because the EU pediatric legislation did not enter into force until 2007.
As noted previously, there was a difference between the 2 cohorts in the therapeutic areas studied most commonly in developing countries, from infectious diseases, cardiology, metabolism and endocrinology, and neurology, to infectious diseases, neurology, and pulmonary/allergy.Arguablythischangeis reassuring, because asthma is becoming a major health issue in many developing countries. 15 The neurologic indications studied in developing countries in the 2007-2010 cohort were seizures, neurogenic bladder, and migraine. Pediatric seizures are a serious condition, and the prevalence is higher in developing countries than in the United States. 16 Neurogenic bladder is also a common pediatric problem in developing countries, and the serious potential morbidity justifies involvement of these countries in the relevant clinical trials. [17] [18] [19] Pediatric migraine was studied in Latin America, where the prevalence of migraine is similar to that in the United States and Europe. 20 It was noted that for a few therapeutic areas, such as JIA, bipolar disorder/ schizophrenia, and hypertension, a relatively high percentage of patients were recruited from developing or transition countries. Although they do not present a major public health problem, these conditions occur in developing countries, and the participating countries enrolled relatively small numbers of patients. Taking into account the epidemiology of the condition under study, the number of patients enrolled from a country, and the size of its pediatric population, few patients (,0.2%) from developing countries were included in studies that could be described as irrelevant or inappropriate for that particular country.
This study is limited because we have no earlier data for vaccine trials, and so it is not possible to comment on any regional changes over time in trial locations or patient involvement. However, we now have baseline data with which to compare vaccine trial locations in a future cohort. Another limitation is the method used to obtain the cohort of studies. a Data set of studies with complete data on location (n = 201 studies). b Data set of studies with complete data on location and patient number (n = 119 studies).
contained sites outside the United States and approximately one-fifth (23%) involved developing or transition countries. For drugs and biological trials, the great majority of patients (89%) were recruited from developed countries, whereas, for vaccine trials, a lesser majority of patients (52%) were enrolled from developing countries.
In general, the most commonly studied therapeutic areas in developing or transition countries were appropriate for their public health needs and patients were not enrolled into studies inappropriately from this perspective. Regulatory authorities and other stake holders should continue to review the locations of pediatric clinical trials, the numbers of patients enrolled per location, and the design of the trials and the indications studied. Our current analysis provides a useful set of benchmarks against which to measure future changes in the involvement of developing or transition countries in pediatric clinical trials. 
